How can I benefit from ADCETRIS?
Before making decisions about your treatment, see how others have responded to ADCETRIS
Select each tab to see ADCETRIS study results for people with certain types of T-cell lymphoma
Previously untreated PTCL
Relapsed pcALCL or MF
Relapsed sALCL
ADCETRIS is used with chemotherapy (CHP) for the treatment of adults with previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing T-cell lymphoma.
In a large clinical study of 452 people with peripheral T-cell lymphoma, ADCETRIS plus CHP was compared to CHOP, a traditional and more commonly used chemotherapy option.
- 226 people were treated with ADCETRIS plus CHP
- 226 people were treated with CHOP
Select the button above to view side effects.
Study results
Main study results
Used to support the FDA approval of ADCETRIS plus CHP. The average follow-up time for the main study was 3.5 years.
ADCETRIS offered patients more time without cancer progression
ADCETRIS plus CHP reduced the risk of:
- Cancer growing or spreading
- Or needing additional anticancer therapy
- Or death
by 29% when compared to CHOP chemotherapy alone.
At 3 years, 57% of ADCETRIS plus CHP patients were alive without their cancer growing or spreading, or needing additional anticancer therapy, compared to 44% of those treated with CHOP.
Patients lived longer
More people treated with ADCETRIS plus CHP lived longer than those treated with CHOP.
Patients saw tumor size reduced
More people treated with ADCETRIS plus CHP saw their tumors get smaller or become undetectable compared to those receiving CHOP.
Exploratory follow-up at 5 years
The following results are from an exploratory analysis. The study was not designed to find differences between treatment groups at 5 years. Investigators looked at what happened in the study without determining a definitive benefit. Conclusions cannot necessarily be based on this information. The average follow-up time for the exploratory analysis was 5.6 years.
Patients were alive without cancer progression
ADCETRIS plus CHP reduced the risk of:
- Cancer growing or spreading
- Or needing additional anticancer therapy
- Or death
by 30% when compared to CHOP chemotherapy alone.
At 5 years, 51% of ADCETRIS plus CHP patients were alive without their cancer growing or spreading, or needing additional anticancer therapy, compared to 43% of those treated with CHOP.
Find out if ADCETRIS may be an option for you.
Glossary
CHOP: A combination of 4 chemotherapies—cyclophosphamide, doxorubicin, vincristine, and prednisone.
CHP: A combination of 3 chemotherapies—cyclophosphamide, doxorubicin, and prednisone.
Complete remission: When all signs of cancer in your body are undetected following treatment.
Partial remission: A decrease in the size of a tumor, or the amount of cancer in your body, following treatment. Some cancer remains.
FDA: Food and Drug Administration.
Interested in starting ADCETRIS?
The science of ADCETRIS treatment
ADCETRIS is not like traditional chemotherapy. It is an antibody drug conjugate made up of 3 parts: an antibody, a drug, and a linker.
Antibody
An antibody that finds CD30, a protein on the surface of certain cells. Antibodies are proteins made by the body’s immune system. The antibody that makes up ADCETRIS is made in a laboratory.
Drug
A drug that is designed to cause cell death.
Linker
A linker that attaches the drug to the antibody and releases the drug inside the cell.
How does ADCETRIS work?
Step 1
ADCETRIS aims to attach to cells that have a protein on their surface called CD30.
Step 2
Once attached, ADCETRIS is brought into the cell and released.
Step 3
The drug stops the cell from being able to grow and divide, causing the cell to die.
CD30 is found on cancer cells of peripheral T-cell lymphomas, including these types:
- Adult T-cell lymphoma/leukemia
- Angioimmunoblastic T-cell lymphoma
- Enteropathy-associated T-cell lymphoma
- Peripheral T-cell lymphoma not otherwise specified
- Cutaneous T-cell lymphomas
- Systemic anaplastic large cell lymphoma
ADCETRIS targets a protein called CD30 found on the surface of cells, including peripheral T-cell lymphoma cells. Even though ADCETRIS is a CD30-directed treatment, it can still affect normal cells and can cause side effects. Talk to your doctor if you have more questions about possible side effects.